“Breath Biomarkers of Infection” in the Analytical Scientist

From cancer to diabetes to the recent rise of COVID-19, we will all likely come face-to-face with a threat to our health. Contemporary medicine has ever-improving tools to identify and combat diseases, but there are gaps – in speed, in invasiveness, in coverage, in access, and in accuracy. Can we do better? And how can we ensure that new approaches provide the same level of diagnostic potential as those currently in service?

Jane Hill, Associate Professor of Engineering, and Billy Boyle, CEO of Owlstone Medical, explain how their research in the area of breath analysis is opening new diagnostic doors.